Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05720325 · ClinicalTrials.gov registry record · Phase 2
Dupilumab Effects Against Aeroallergen Challenge
A Phase 2 study of Asthma, Allergic, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 2
- Study locations
NCT05720325: Recruiting Phase 2 study of Asthma, Allergic, sponsored by The University of Texas Health Science Center at San Antonio.
NCT05720325 is a Phase 2 study of Asthma, Allergic that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05720325, a Phase 2 study of Asthma, Allergic, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 2
- Study locations
Study Summary
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
Primary Outcome
The overall (longitudinal) change in the ACC HDM exposure-induced nasal airway gene expression profiles observed during the first HDM exposure (visit 3; pre-randomization) and during the three on-treatment HDM exposures (visits 7, 11, and 15)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dupilumab
- OTHER House Dust Mites (HDM)
Study Locations (2)
Texas
- Biogenics Research Chamber - San Antonio
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2023-03-29 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT05720325 shows while recruiting
NCT05720325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Asthma, Allergic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05720325 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05720325 about?
NCT05720325 is a clinical study titled "Dupilumab Effects Against Aeroallergen Challenge". The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
What is the current status of trial NCT05720325?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2023-03-29. Estimated completion is 2027-11.
What conditions does trial NCT05720325 study?
This clinical trial studies the following conditions: Asthma, Allergic.
What interventions are being tested in trial NCT05720325?
The interventions under investigation include: Placebo (OTHER), Dupilumab (DRUG), House Dust Mites (HDM) (OTHER).
Who is sponsoring clinical trial NCT05720325?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05720325 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma, Allergic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05720325's enrollment target sits among peer trials
88 803rd of 2000 higher than 1,192 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI